[{"id":"f73113c5-10a0-4d17-963d-5c3a022450a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07039877","created_at":"2025-06-28T13:39:04.007Z","updated_at":"2025-06-28T13:39:04.007Z","phase":"Phase 2","brief_title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","source_id_and_acronym":"NCT07039877","lead_sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • bortezomib • itraconazole"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/02/2025","start_date":" 01/02/2025","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-06-26"},{"id":"afc34dd5-440d-4768-b2d3-1f68bbdafbb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05470491","created_at":"2022-07-22T11:56:13.684Z","updated_at":"2025-02-25T13:54:33.177Z","phase":"Phase 1/2","brief_title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","source_id_and_acronym":"NCT05470491","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-20"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"70895122-f43e-478e-b06c-44c96910d6ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265872","created_at":"2021-04-20T09:53:17.764Z","updated_at":"2025-02-25T16:44:48.890Z","phase":"Phase 1","brief_title":"Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC","source_id_and_acronym":"NCT04265872","lead_sponsor":"Baylor Research Institute","biomarkers":" ER • HRD","pipe":" | ","alterations":" HRD • ER negative","tags":["ER • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-05"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"de01f4b4-b380-45e4-a05f-0573156a9b1c","acronym":"AAML1031","url":"https://clinicaltrials.gov/study/NCT01371981","created_at":"2021-01-18T05:37:13.447Z","updated_at":"2025-02-25T16:51:07.072Z","phase":"Phase 3","brief_title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01371981 - AAML1031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1645","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-04"},{"id":"facf7f83-63bf-49f3-a6fb-2b75c0782dba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848687","created_at":"2023-05-08T15:04:02.177Z","updated_at":"2025-02-25T17:26:10.730Z","phase":"Phase 1/2","brief_title":"TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II","source_id_and_acronym":"NCT05848687","lead_sponsor":"Tanja Andrea Gruber","biomarkers":" KMT2A","pipe":" | ","alterations":" CD19 positive","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Blincyto (blinatumomab) • Zolinza (vorinostat) • dexamethasone • mitoxantrone • Komzifti (ziftomenib) • mercaptopurine"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/03/2023","start_date":" 11/03/2023","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2025-01-31"},{"id":"c2530d5f-2067-4089-83d8-8b338ff98d19","acronym":"","url":"https://clinicaltrials.gov/study/NCT06245629","created_at":"2025-02-26T11:14:39.219Z","updated_at":"2025-02-26T11:14:39.219Z","phase":"","brief_title":"Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","source_id_and_acronym":"NCT06245629","lead_sponsor":"Uppsala University","biomarkers":" SLC1A5","pipe":"","alterations":" ","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • bendamustine • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/24/2024","start_date":" 11/24/2024","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-11-28"},{"id":"61e57503-680e-4667-ac9e-45a1209fdaaf","acronym":"TT4B","url":"https://clinicaltrials.gov/study/NCT00734877","created_at":"2021-01-18T02:46:06.475Z","updated_at":"2025-02-25T14:55:10.781Z","phase":"Phase 3","brief_title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","source_id_and_acronym":"NCT00734877 - TT4B","lead_sponsor":"University of Arkansas","biomarkers":" TP53","pipe":" | ","alterations":" TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dexamethasone • thalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 382","initiation":"Initiation: 07/01/2008","start_date":" 07/01/2008","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-07-03"},{"id":"6c8187f2-a1a7-4e0d-9839-99324cab5154","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022939","created_at":"2023-09-05T18:12:25.015Z","updated_at":"2024-07-02T16:34:27.373Z","phase":"Phase 3","brief_title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","source_id_and_acronym":"NCT06022939","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/29/2030","primary_completion_date":" 07/29/2030","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2024-06-11"},{"id":"5077dab5-cc6d-4875-b03f-04b2ac602ed5","acronym":"NFL-BIOPAIN","url":"https://clinicaltrials.gov/study/NCT05781425","created_at":"2023-03-23T14:02:47.910Z","updated_at":"2024-07-02T16:34:37.446Z","phase":"","brief_title":"Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?","source_id_and_acronym":"NCT05781425 - NFL-BIOPAIN","lead_sponsor":"Odense University Hospital","biomarkers":" NEFL","pipe":"","alterations":" ","tags":["NEFL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-07"},{"id":"d888b6c9-4b44-4498-aef7-22dac96f744f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01163357","created_at":"2021-01-18T04:38:10.114Z","updated_at":"2024-07-02T16:35:00.426Z","phase":"Phase 1","brief_title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","source_id_and_acronym":"NCT01163357","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • sirolimus • melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/28/2011","start_date":" 01/28/2011","primary_txt":" Primary completion: 07/20/2019","primary_completion_date":" 07/20/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"adf70f50-0fc0-4474-a764-ea766f835694","acronym":"","url":"https://clinicaltrials.gov/study/NCT01286272","created_at":"2021-01-18T05:13:11.418Z","updated_at":"2024-07-02T16:35:02.742Z","phase":"Phase 2","brief_title":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01286272","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":"","alterations":" ","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 04/08/2011","start_date":" 04/08/2011","primary_txt":" Primary completion: 05/24/2017","primary_completion_date":" 05/24/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-05-17"},{"id":"b2fc6887-a084-4aa0-93a1-942ca0ac28d0","acronym":"MUKnineb","url":"https://clinicaltrials.gov/study/NCT03188172","created_at":"2021-01-18T15:43:10.893Z","updated_at":"2025-02-25T14:26:26.313Z","phase":"Phase 2","brief_title":"MUK Nine b: OPTIMUM Treatment Protocol","source_id_and_acronym":"NCT03188172 - MUKnineb","lead_sponsor":"University of Leeds","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • cyclophosphamide • Darzalex (daratumumab) • dexamethasone • melphalan • Neupogen (filgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-05-14"},{"id":"5c1628c8-1205-4db1-a7b7-2787115fd94d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03620903","created_at":"2021-01-18T17:47:32.533Z","updated_at":"2024-07-02T16:35:04.143Z","phase":"Phase 2","brief_title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT03620903","lead_sponsor":"Christian Buske","biomarkers":" CD20 • CD5 • MME • FCER2","pipe":" | ","alterations":" CD5 positive","tags":["CD20 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 09/11/2019","start_date":" 09/11/2019","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-05-13"},{"id":"68c8de81-678c-4539-bf83-7836e390592f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01788020","created_at":"2021-01-18T07:53:54.903Z","updated_at":"2024-07-02T16:35:04.236Z","phase":"Phase 3","brief_title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT01788020","lead_sponsor":"University of Ulm","biomarkers":" CD20 • CD5 • MME • FCER2","pipe":" | ","alterations":" CD20 positive • CD5 positive","tags":["CD20 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • dexamethasone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-05-13"},{"id":"42ab6aff-9345-491e-bdf9-65c8c94e1c52","acronym":"","url":"https://clinicaltrials.gov/study/NCT05895201","created_at":"2023-06-09T09:09:14.295Z","updated_at":"2024-07-02T16:35:07.163Z","phase":"Phase 1/2","brief_title":"High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD","source_id_and_acronym":"NCT05895201","lead_sponsor":"Indiana University","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-29"},{"id":"d9205d85-be27-4b6c-84a5-c85c6627b25a","acronym":"NCI-2018-01198","url":"https://clinicaltrials.gov/study/NCT03136146","created_at":"2021-01-18T15:27:28.397Z","updated_at":"2024-07-02T16:35:12.329Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","source_id_and_acronym":"NCT03136146 - NCI-2018-01198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-29"},{"id":"a47b9baf-315f-4d17-8189-36a9e437a098","acronym":"BORXPTEN","url":"https://clinicaltrials.gov/study/NCT06029998","created_at":"2023-09-08T20:10:19.869Z","updated_at":"2024-07-02T16:35:14.989Z","phase":"Phase 2","brief_title":"Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion","source_id_and_acronym":"NCT06029998 - BORXPTEN","lead_sponsor":"University of Utah","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN deletion","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-03-13"},{"id":"d0d47c61-61e0-4557-9a9c-103d7e9e6b56","acronym":"","url":"https://clinicaltrials.gov/study/NCT01695941","created_at":"2021-01-29T07:03:45.178Z","updated_at":"2024-07-02T16:35:15.783Z","phase":"Phase 1","brief_title":"Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01695941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • alisertib (MLN8237) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/31/2012","start_date":" 08/31/2012","primary_txt":" Primary completion: 05/29/2018","primary_completion_date":" 05/29/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-03-07"},{"id":"6d194b66-a36a-4049-9be1-f272a6096889","acronym":"","url":"https://clinicaltrials.gov/study/NCT03117751","created_at":"2021-01-18T15:21:39.440Z","updated_at":"2024-07-02T16:35:16.300Z","phase":"Phase 2/3","brief_title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","source_id_and_acronym":"NCT03117751","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BCL2 • CEP72","pipe":"","alterations":" ","tags":["BCL2 • CEP72"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • bortezomib • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • Zolinza (vorinostat) • clofarabine • idarubicin hydrochloride • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Erwinase (erwinia asparaginase) • Purixan (mercaptopurine oral suspension) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 790","initiation":"Initiation: 03/29/2017","start_date":" 03/29/2017","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-03-05"},{"id":"cecdbaf1-ddd6-42e8-84b3-c89f7f4d1267","acronym":"BORTEM-17","url":"https://clinicaltrials.gov/study/NCT03643549","created_at":"2021-07-05T17:16:33.314Z","updated_at":"2024-07-02T16:35:17.017Z","phase":"Phase 1/2","brief_title":"Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)","source_id_and_acronym":"NCT03643549 - BORTEM-17","lead_sponsor":"Haukeland University Hospital","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/30/2018","start_date":" 08/30/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-29"},{"id":"9c1f7fff-bdbd-42f6-b86e-29192b0576bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05850286","created_at":"2023-05-09T14:04:26.586Z","updated_at":"2024-07-02T16:35:18.522Z","phase":"Phase 2","brief_title":"A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities","source_id_and_acronym":"NCT05850286","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" TP53 • SDC1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-02-20"},{"id":"ea532b6b-8892-42a5-b856-74551292fcbd","acronym":"ECOG-ACRIN E1411","url":"https://clinicaltrials.gov/study/NCT01415752","created_at":"2021-01-18T05:49:42.946Z","updated_at":"2024-07-02T16:35:27.710Z","phase":"Phase 2","brief_title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT01415752 - ECOG-ACRIN E1411","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CCND1 • CD4","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • bortezomib • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 373","initiation":"Initiation: 08/09/2012","start_date":" 08/09/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2023-11-29"}]